Regenxbio trumpets one-year data for Hunter syndrome gene therapy after FDA extended its review

Regenxbio released new data that it hopes will get its gene therapy for a rare disease across the regulatory finish line. The company said Friday that in a one-year look at 13 patients with Hunter ...